Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients
Manuel Monreal/X
Aug 31, 2025, 07:05

RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients

 

Manuel Monreal, coordinator of the RIETE registry, posted on X:

”The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers

No major differences in GU or CI cancers

Should all cancer patients with acute VTE receive the same treatment strategy?”

Find it here.

Title: Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry Analysis

Authors: Javier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, David Jiménez, Aurora Villalobos, Luciano López-Jiménez, Montserrat Pérez-Pinar, Javier Pagán-Escribano, Maurizio Ciammaichella, Manuel Monreal

 

VTE vs Bleeding risk in cancer patients

 

Stay updated with Hemostasis Today.

Aurora Villalobos Behnood Bikdeli Bleeding Risk cancer Cihan Ay David Jimenez Hematology Hemostasis Today Javier Pagán-Escribano Javier Trujillo-Santos Luciano López-Jiménez Manuel Monreal Maurizio Ciammaichella Montserrat Pérez-Pinar PE Pulmonary embolism RIETE registry venous thromboembolism (VTE)
NewsFeed